GW Pharma Ramping Up Production in Expectation of FDA Approval

The British company GW Pharmaceuticals is reportedly increasing its manufacturing capacity for medical marijuana and a specific cannabis-based drug it has developed for epileptics called Epidiolex. That’s in expectation that the U.S. Food and Drug Administration will give the company the green light sometime either next year or early 2017 to begin widespread distribution, according to the Telegraph.

Although the company had hoped to obtain FDA approval early next year, it has still increased production 20 times already, and is planning to double production levels next year, the firm’s CEO told the Telegraph. The company plans

...

GW Pharma Ramping Up Production in Expectation of FDA Approval is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs